MA53150A - Composés de benzimidazole en tant qu'inhibiteurs de c-kit - Google Patents
Composés de benzimidazole en tant qu'inhibiteurs de c-kitInfo
- Publication number
- MA53150A MA53150A MA053150A MA53150A MA53150A MA 53150 A MA53150 A MA 53150A MA 053150 A MA053150 A MA 053150A MA 53150 A MA53150 A MA 53150A MA 53150 A MA53150 A MA 53150A
- Authority
- MA
- Morocco
- Prior art keywords
- benzimidazole compounds
- kit inhibitors
- inhibitors
- kit
- benzimidazole
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434839P | 2016-12-15 | 2016-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53150A true MA53150A (fr) | 2021-05-26 |
Family
ID=60888754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053150A MA53150A (fr) | 2016-12-15 | 2017-12-14 | Composés de benzimidazole en tant qu'inhibiteurs de c-kit |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11117883B2 (fr) |
| EP (1) | EP3555066A1 (fr) |
| JP (2) | JP7158383B2 (fr) |
| KR (1) | KR20190092538A (fr) |
| CN (3) | CN110291081B (fr) |
| AU (3) | AU2017376629B2 (fr) |
| BR (1) | BR112019012224A2 (fr) |
| CA (1) | CA3047107A1 (fr) |
| EA (1) | EA201991197A1 (fr) |
| IL (3) | IL314209A (fr) |
| MA (1) | MA53150A (fr) |
| MX (2) | MX390348B (fr) |
| WO (1) | WO2018112140A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291081B (zh) * | 2016-12-15 | 2023-01-31 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
| CN109320503B (zh) * | 2018-12-10 | 2022-07-01 | 怀化学院 | 苯并咪唑炔胺类化合物的无金属一锅合成方法 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (fr) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| CA3235986A1 (fr) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Composes cd73 |
| EP4452414A2 (fr) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées |
| EP4667056A1 (fr) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| EP4638436A1 (fr) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| EP4695260A1 (fr) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Composés modulateurs de kras |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024300557A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (fr) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (fr) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Inhibiteurs azaspiro de wrn |
| WO2025245003A1 (fr) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2026039365A1 (fr) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Composés de modulation de kras |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| MXPA06002018A (es) * | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Bencimidazolilo n-sustituidos inhibidores de c-kit. |
| KR20070086865A (ko) * | 2004-12-01 | 2007-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | Ｎ-치환된 벤즈이미다졸일 ｃ-ｋｉｔ 억제제 및 조합적인벤즈이미다졸 라이브러리 |
| UA94055C2 (en) * | 2005-08-30 | 2011-04-11 | Новартис Аг | Substituted benzimidazoles and methods of preparation |
| EP2762142A1 (fr) * | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions pour le traitement du cancer |
| JP5740409B2 (ja) * | 2009-11-13 | 2015-06-24 | ジェノスコ | キナーゼ阻害剤 |
| CN103582478A (zh) * | 2011-04-07 | 2014-02-12 | 阿里亚德医药股份有限公司 | 治疗神经退行性疾病的方法和组合物 |
| CN103664787B (zh) * | 2012-09-17 | 2015-09-09 | 南京圣和药业股份有限公司 | 炔杂芳环化合物及其应用 |
| CA2815506C (fr) * | 2012-12-12 | 2018-12-11 | Ariad Pharmaceuticals, Inc. | Formes cristallines de 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperaz in-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| GB2522226A (en) * | 2014-01-17 | 2015-07-22 | Agency Science Tech & Res | Heteroaryl alkyne derivatives and uses thereof |
| CN110291081B (zh) * | 2016-12-15 | 2023-01-31 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
-
2017
- 2017-12-14 CN CN201780085539.3A patent/CN110291081B/zh not_active Expired - Fee Related
- 2017-12-14 JP JP2019531992A patent/JP7158383B2/ja active Active
- 2017-12-14 BR BR112019012224-9A patent/BR112019012224A2/pt not_active Application Discontinuation
- 2017-12-14 EA EA201991197A patent/EA201991197A1/ru unknown
- 2017-12-14 IL IL314209A patent/IL314209A/en unknown
- 2017-12-14 CN CN202211731994.5A patent/CN116178343A/zh active Pending
- 2017-12-14 MA MA053150A patent/MA53150A/fr unknown
- 2017-12-14 IL IL287517A patent/IL287517B2/en unknown
- 2017-12-14 CA CA3047107A patent/CA3047107A1/fr active Pending
- 2017-12-14 CN CN202211737801.7A patent/CN116283910A/zh active Pending
- 2017-12-14 WO PCT/US2017/066299 patent/WO2018112140A1/fr not_active Ceased
- 2017-12-14 AU AU2017376629A patent/AU2017376629B2/en not_active Ceased
- 2017-12-14 KR KR1020197020159A patent/KR20190092538A/ko not_active Abandoned
- 2017-12-14 EP EP17822994.4A patent/EP3555066A1/fr not_active Withdrawn
- 2017-12-14 MX MX2019007080A patent/MX390348B/es unknown
- 2017-12-14 US US16/469,535 patent/US11117883B2/en not_active Expired - Fee Related
-
2019
- 2019-06-12 IL IL267260A patent/IL267260B2/en unknown
- 2019-06-14 MX MX2022002581A patent/MX2022002581A/es unknown
-
2021
- 2021-08-12 US US17/400,820 patent/US20220064144A1/en not_active Abandoned
-
2022
- 2022-02-18 AU AU2022201082A patent/AU2022201082B2/en not_active Ceased
- 2022-10-11 JP JP2022163367A patent/JP2022185110A/ja active Pending
-
2024
- 2024-02-01 AU AU2024200624A patent/AU2024200624A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017376629B2 (en) | 2021-11-25 |
| CN110291081B (zh) | 2023-01-31 |
| IL287517B2 (en) | 2024-12-01 |
| IL287517A (en) | 2021-12-01 |
| JP2022185110A (ja) | 2022-12-13 |
| EP3555066A1 (fr) | 2019-10-23 |
| CN110291081A (zh) | 2019-09-27 |
| WO2018112140A1 (fr) | 2018-06-21 |
| CA3047107A1 (fr) | 2018-06-21 |
| IL267260A (en) | 2019-08-29 |
| IL267260B (en) | 2022-10-01 |
| AU2022201082A1 (en) | 2022-03-10 |
| JP7158383B2 (ja) | 2022-10-21 |
| US20200039958A1 (en) | 2020-02-06 |
| EA201991197A1 (ru) | 2020-01-13 |
| IL314209A (en) | 2024-09-01 |
| IL287517B1 (en) | 2024-08-01 |
| MX2019007080A (es) | 2019-10-15 |
| MX390348B (es) | 2025-03-20 |
| IL267260B2 (en) | 2023-02-01 |
| MX2022002581A (es) | 2022-03-22 |
| AU2017376629A1 (en) | 2019-07-04 |
| CN116283910A (zh) | 2023-06-23 |
| JP2020503299A (ja) | 2020-01-30 |
| US20220064144A1 (en) | 2022-03-03 |
| KR20190092538A (ko) | 2019-08-07 |
| CN116178343A (zh) | 2023-05-30 |
| AU2022201082B2 (en) | 2023-11-02 |
| AU2024200624A1 (en) | 2024-02-22 |
| US11117883B2 (en) | 2021-09-14 |
| BR112019012224A2 (pt) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA52063A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| EP3533787A4 (fr) | Composé de pyridone en tant qu'inhibiteur de c-met | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| EP3386981A4 (fr) | Hétérocycles utiles en tant qu'agents anticancereux | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA46091A (fr) | Composés biaryles utiles en tant qu'immunomodulateurs | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |